Tissue-engineered autologous urethras for patients who need reconstruction

An observational study

Atlantida Raya-Rivera, Diego R. Esquiliano, James J. Yoo, Esther Lopez-Bayghen, Shay Soker, Anthony Atala

Research output: Contribution to journalArticle

283 Citations (Scopus)

Abstract

Complex urethral problems can occur as a result of injury, disease, or congenital defects and treatment options are often limited. Urethras, similar to other long tubularised tissues, can stricture after reconstruction. We aimed to assess the effectiveness of tissue-engineered urethras using patients' own cells in patients who needed urethral reconstruction. Five boys who had urethral defects were included in the study. A tissue biopsy was taken from each patient, and the muscle and epithelial cells were expanded and seeded onto tubularised polyglycolic acid:poly(lactide-co-glycolide acid) scaffolds. Patients then underwent urethral reconstruction with the tissue-engineered tubularised urethras. We took patient history, asked patients to complete questionnaires from the International Continence Society (ICS), and did urine analyses, cystourethroscopy, cystourethrography, and flow measurements at 3, 6, 12, 24, 36, 48, 60, and 72 months after surgery. We did serial endoscopic cup biopsies at 3, 12, and 36 months, each time in a different area of the engineered urethras. Patients had surgery between March 19, 2004, and July 20, 2007. Follow-up was completed by July 31, 2010. Median age was 11 years (range 10-14) at time of surgery and median follow-up was 71 months (range 36-76 months). AE1/AE3, α actin, desmin, and myosin antibodies confirmed the presence of cells of epithelial and muscle lineages on all cultures. The median end maximum urinary flow rate was 27·1 mL/s (range 16-28), and serial radiographic and endoscopic studies showed the maintenance of wide urethral calibres without strictures. Urethral biopsies showed that the engineered grafts had developed a normal appearing architecture by 3 months after implantation. Tubularised urethras can be engineered and remain functional in a clinical setting for up to 6 years. These engineered urethras can be used in patients who need complex urethral reconstruction. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

Original languageEnglish
Pages (from-to)1175-1182
Number of pages8
JournalThe Lancet
Volume377
Issue number9772
DOIs
StatePublished - Apr 2 2011
Externally publishedYes

Fingerprint

Urethra
Observational Studies
Biopsy
Muscle Cells
Pathologic Constriction
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Epithelial Cells
Polyglycolic Acid
Polyglactin 910
Desmin
National Institutes of Health (U.S.)
Myosins
Actins
Maintenance
Urine
Transplants
Acids
Antibodies
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Raya-Rivera, A., Esquiliano, D. R., Yoo, J. J., Lopez-Bayghen, E., Soker, S., & Atala, A. (2011). Tissue-engineered autologous urethras for patients who need reconstruction: An observational study. The Lancet, 377(9772), 1175-1182. https://doi.org/10.1016/S0140-6736(10)62354-9

Tissue-engineered autologous urethras for patients who need reconstruction : An observational study. / Raya-Rivera, Atlantida; Esquiliano, Diego R.; Yoo, James J.; Lopez-Bayghen, Esther; Soker, Shay; Atala, Anthony.

In: The Lancet, Vol. 377, No. 9772, 02.04.2011, p. 1175-1182.

Research output: Contribution to journalArticle

Raya-Rivera, A, Esquiliano, DR, Yoo, JJ, Lopez-Bayghen, E, Soker, S & Atala, A 2011, 'Tissue-engineered autologous urethras for patients who need reconstruction: An observational study', The Lancet, vol. 377, no. 9772, pp. 1175-1182. https://doi.org/10.1016/S0140-6736(10)62354-9
Raya-Rivera A, Esquiliano DR, Yoo JJ, Lopez-Bayghen E, Soker S, Atala A. Tissue-engineered autologous urethras for patients who need reconstruction: An observational study. The Lancet. 2011 Apr 2;377(9772):1175-1182. https://doi.org/10.1016/S0140-6736(10)62354-9
Raya-Rivera, Atlantida ; Esquiliano, Diego R. ; Yoo, James J. ; Lopez-Bayghen, Esther ; Soker, Shay ; Atala, Anthony. / Tissue-engineered autologous urethras for patients who need reconstruction : An observational study. In: The Lancet. 2011 ; Vol. 377, No. 9772. pp. 1175-1182.
@article{1742fd40984e41eba30a93929420baba,
title = "Tissue-engineered autologous urethras for patients who need reconstruction: An observational study",
abstract = "Complex urethral problems can occur as a result of injury, disease, or congenital defects and treatment options are often limited. Urethras, similar to other long tubularised tissues, can stricture after reconstruction. We aimed to assess the effectiveness of tissue-engineered urethras using patients' own cells in patients who needed urethral reconstruction. Five boys who had urethral defects were included in the study. A tissue biopsy was taken from each patient, and the muscle and epithelial cells were expanded and seeded onto tubularised polyglycolic acid:poly(lactide-co-glycolide acid) scaffolds. Patients then underwent urethral reconstruction with the tissue-engineered tubularised urethras. We took patient history, asked patients to complete questionnaires from the International Continence Society (ICS), and did urine analyses, cystourethroscopy, cystourethrography, and flow measurements at 3, 6, 12, 24, 36, 48, 60, and 72 months after surgery. We did serial endoscopic cup biopsies at 3, 12, and 36 months, each time in a different area of the engineered urethras. Patients had surgery between March 19, 2004, and July 20, 2007. Follow-up was completed by July 31, 2010. Median age was 11 years (range 10-14) at time of surgery and median follow-up was 71 months (range 36-76 months). AE1/AE3, α actin, desmin, and myosin antibodies confirmed the presence of cells of epithelial and muscle lineages on all cultures. The median end maximum urinary flow rate was 27·1 mL/s (range 16-28), and serial radiographic and endoscopic studies showed the maintenance of wide urethral calibres without strictures. Urethral biopsies showed that the engineered grafts had developed a normal appearing architecture by 3 months after implantation. Tubularised urethras can be engineered and remain functional in a clinical setting for up to 6 years. These engineered urethras can be used in patients who need complex urethral reconstruction. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.",
author = "Atlantida Raya-Rivera and Esquiliano, {Diego R.} and Yoo, {James J.} and Esther Lopez-Bayghen and Shay Soker and Anthony Atala",
year = "2011",
month = "4",
day = "2",
doi = "10.1016/S0140-6736(10)62354-9",
language = "English",
volume = "377",
pages = "1175--1182",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9772",

}

TY - JOUR

T1 - Tissue-engineered autologous urethras for patients who need reconstruction

T2 - An observational study

AU - Raya-Rivera, Atlantida

AU - Esquiliano, Diego R.

AU - Yoo, James J.

AU - Lopez-Bayghen, Esther

AU - Soker, Shay

AU - Atala, Anthony

PY - 2011/4/2

Y1 - 2011/4/2

N2 - Complex urethral problems can occur as a result of injury, disease, or congenital defects and treatment options are often limited. Urethras, similar to other long tubularised tissues, can stricture after reconstruction. We aimed to assess the effectiveness of tissue-engineered urethras using patients' own cells in patients who needed urethral reconstruction. Five boys who had urethral defects were included in the study. A tissue biopsy was taken from each patient, and the muscle and epithelial cells were expanded and seeded onto tubularised polyglycolic acid:poly(lactide-co-glycolide acid) scaffolds. Patients then underwent urethral reconstruction with the tissue-engineered tubularised urethras. We took patient history, asked patients to complete questionnaires from the International Continence Society (ICS), and did urine analyses, cystourethroscopy, cystourethrography, and flow measurements at 3, 6, 12, 24, 36, 48, 60, and 72 months after surgery. We did serial endoscopic cup biopsies at 3, 12, and 36 months, each time in a different area of the engineered urethras. Patients had surgery between March 19, 2004, and July 20, 2007. Follow-up was completed by July 31, 2010. Median age was 11 years (range 10-14) at time of surgery and median follow-up was 71 months (range 36-76 months). AE1/AE3, α actin, desmin, and myosin antibodies confirmed the presence of cells of epithelial and muscle lineages on all cultures. The median end maximum urinary flow rate was 27·1 mL/s (range 16-28), and serial radiographic and endoscopic studies showed the maintenance of wide urethral calibres without strictures. Urethral biopsies showed that the engineered grafts had developed a normal appearing architecture by 3 months after implantation. Tubularised urethras can be engineered and remain functional in a clinical setting for up to 6 years. These engineered urethras can be used in patients who need complex urethral reconstruction. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

AB - Complex urethral problems can occur as a result of injury, disease, or congenital defects and treatment options are often limited. Urethras, similar to other long tubularised tissues, can stricture after reconstruction. We aimed to assess the effectiveness of tissue-engineered urethras using patients' own cells in patients who needed urethral reconstruction. Five boys who had urethral defects were included in the study. A tissue biopsy was taken from each patient, and the muscle and epithelial cells were expanded and seeded onto tubularised polyglycolic acid:poly(lactide-co-glycolide acid) scaffolds. Patients then underwent urethral reconstruction with the tissue-engineered tubularised urethras. We took patient history, asked patients to complete questionnaires from the International Continence Society (ICS), and did urine analyses, cystourethroscopy, cystourethrography, and flow measurements at 3, 6, 12, 24, 36, 48, 60, and 72 months after surgery. We did serial endoscopic cup biopsies at 3, 12, and 36 months, each time in a different area of the engineered urethras. Patients had surgery between March 19, 2004, and July 20, 2007. Follow-up was completed by July 31, 2010. Median age was 11 years (range 10-14) at time of surgery and median follow-up was 71 months (range 36-76 months). AE1/AE3, α actin, desmin, and myosin antibodies confirmed the presence of cells of epithelial and muscle lineages on all cultures. The median end maximum urinary flow rate was 27·1 mL/s (range 16-28), and serial radiographic and endoscopic studies showed the maintenance of wide urethral calibres without strictures. Urethral biopsies showed that the engineered grafts had developed a normal appearing architecture by 3 months after implantation. Tubularised urethras can be engineered and remain functional in a clinical setting for up to 6 years. These engineered urethras can be used in patients who need complex urethral reconstruction. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

UR - http://www.scopus.com/inward/record.url?scp=79953283872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953283872&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)62354-9

DO - 10.1016/S0140-6736(10)62354-9

M3 - Article

VL - 377

SP - 1175

EP - 1182

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9772

ER -